Skip to content
Roboearth – Lifestyle
Author:
Grifols, S.A.
Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency
August 10, 2026
Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins
July 16, 2026
Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.
June 16, 2026
Grifols Shares Results From its Chronos Platform Identifying Early Molecular Changes Associated with Parkinson’s Disease
March 17, 2026